Skip to main content


Liver Cancer

Featured

News
Atezolizumab plus bevacizumab was not considered cost-effective compared with sorafenib for the treatment of unresectable or metastatic HCC, although associated with clinical…
Quiz
True or False: Compared with selective internal radiotherapy, sorafenib is a cost-effective treatment for…
Guideline Updates
NCCN released an update to its guideline for hepatobiliary cancers, featuring updates in HCC, gallbladder cancer,…
Quiz
True or False: Pembrolizumab is not considered a cost-effective second-line therapy for treating HCC.
News
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
Back to Top